303 related articles for article (PubMed ID: 25017668)
21. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
22. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
Vervloet MG; van Ballegooijen AJ
Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
[TBL] [Abstract][Full Text] [Related]
23. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous S; Przech S; Martin J; Garg AX; Sarma S
Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
[TBL] [Abstract][Full Text] [Related]
25. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
26. Current and potential treatment options for hyperphosphatemia.
Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
[TBL] [Abstract][Full Text] [Related]
27. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
29. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
30. The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
Elder GJ; Center J
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():42-46. PubMed ID: 28429551
[TBL] [Abstract][Full Text] [Related]
31. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
[TBL] [Abstract][Full Text] [Related]
32. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
33. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
35. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
[TBL] [Abstract][Full Text] [Related]
36. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
[TBL] [Abstract][Full Text] [Related]
37. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
[TBL] [Abstract][Full Text] [Related]
39. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
[TBL] [Abstract][Full Text] [Related]
40. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
